| 查看: 2466 | 回复: 12 | |||
[求助]
求助来那替尼上市信息？ 已有1人参与
|
|||
| 在网上看到有公司挂来那替尼项目合作信息，在CDE上有来那替尼片的进口申请，但是我却查不到该药的具体上市信息，特此求助，望大侠相帮，谢谢！ |
回复此楼» 收录本帖的淘帖专辑推荐
 颛顼药学 |
» 猜你喜欢
中山大学-第七医院-招科研助理1名（基因设计和克隆、RNA合成）
已经有1人回复
-
26在职申博—生物与医药—抗体/ADC药物方向，江浙沪，有项目，可带资。
已经有1人回复
-
药理学论文润色/翻译怎么收费?
已经有204人回复
-
巴黎萨克雷大学与国家留学基金委合作博士研究生项目-脂质纳米药物/生物材料/多酚递送
已经有10人回复
-
2026申请考核博士自荐-蛋白质组学/AI/药物设计/AIDD/化学生物学
已经有1人回复
-
288分求调剂
已经有0人回复
-
接受药学调剂
已经有11人回复
-
锦州医科大学药用生物材料（专业代码1007Z1）招收调剂考生
已经有0人回复
-
一志愿苏州大学 生物技术与工程（086001） 初试323分，求调剂
已经有0人回复
-
锦州医科大学药用生物材料（专业代码1007Z1）招收调剂考生
已经有1人回复
-
三年实验室工作经历，一志愿华中农业大学微生物，总分288求调剂
已经有0人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 求助阿法替尼合成文献
已经有7人回复
- 【求助】FDA2012年批准新药阿西替尼的专利
已经有7人回复
- 达沙替尼上市时间？
已经有8人回复
- canertinib卡奈替尼这个抗肿瘤药物有没有上市？
已经有4人回复
- 求助奥拉西坦国外上市信息
已经有5人回复
- 【求助】凡德他尼（vandetanib）的上市国家和时间及其专利情况
已经有3人回复
- 【求助】请问不在美国上市的药物可以到什么地方查到药品研发信息？以及专利？
已经有5人回复
- 【求助】国外上市药品的信息
已经有14人回复
- 【求助】如何查日本上市的药物信息
已经有3人回复
- 【求助】伊马替尼的质量标准
已经有8人回复
- 【求助】如何寻找多肽上市药物？有哪些网站？
已经有11人回复
酔欲陶然
木虫 (正式写手)
- 应助: 7 (幼儿园)
- 金币: 3995.6
- 散金: 25
- 帖子: 345
- 在线: 263.5小时
- 虫号: 855206
- 注册: 2009-09-23
- 性别: GG
- 专业: 合成药物化学
|
Puma Biotechnology, under license from Pfizer (previously Wyeth), is developing neratinib (PB-272; HKI-272), an irreversible pan-HER (Erbb1, ErbB2 and ErbB4) tyrosine kinase inhibitor, for the potential oral treatment of HER2-positive cancers, primarily breast cancer In July 2009, worldwide phase III breast cancer trials were initiated by Wyeth in patients who had received prior trastuzumab-based therapy ; in October 2011, following its acquisition of rights, Puma intended to terminate the ongoing Pfizer-sponsored trials , and the company began its own phase III trial in third-line metastatic breast cancer in June 2013 . In July 2014, Puma planned to file the drug for approval in the extended adjuvant setting for breast cancer in 1H15 . Development in other HER2-positive cancer settings is ongoing. In April 2013, a phase II trial in patients with NSCLC was ongoing . In October 2013, a phase II study in patients with other solid tumors with a HER2 mutation was initiated ; in March 2014, initial data from the trial were expected in 2014 |
5楼2014-08-28 09:04:03
6楼2014-08-28 09:30:07
9楼2014-08-28 14:11:11
2楼2014-08-27 16:55:56
3楼2014-08-27 16:58:18
4楼2014-08-28 08:46:35
7楼2014-08-28 11:20:00
8楼2014-08-28 11:22:08
|
Puma Biotechnology, under license from Pfizer (previously Wyeth), is developing neratinib (PB-272; HKI-272), an irreversible pan-HER (Erbb1, ErbB2 and ErbB4) tyrosine kinase inhibitor, for the potential oral treatment of HER2-positive cancers, primarily breast cancer In July 2009, worldwide phase III breast cancer trials were initiated by Wyeth in patients who had received prior trastuzumab-based therapy ; in October 2011, following its acquisition of rights, Puma intended to terminate the ongoing Pfizer-sponsored trials , and the company began its own phase III trial in third-line metastatic breast cancer in June 2013 . In July 2014, Puma planned to file the drug for approval in the extended adjuvant setting for breast cancer in 1H15 . Development in other HER2-positive cancer settings is ongoing. In April 2013, a phase II trial in patients with NSCLC was ongoing . In October 2013, a phase II study in patients with other solid tumors with a HER2 mutation was initiated ; in March 2014, initial data from the trial were expected in 2014 |
10楼2014-08-28 18:00:06
